文献速递冠心病血脂与心血管预防

经皮冠状动脉介入术后联合降脂治疗:RACING 试验的临床实践验证

Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

基于全国队列数据库,经稳定逆概率加权后纳入 72,050 例药物洗脱支架植入后处方瑞舒伐他汀的患者,比较瑞舒伐他汀 10 mg 联合依折麦布 10 mg 与瑞舒伐他汀 20 mg 单药治疗。联合治疗组 3 年主要复合终点发生率低于高强度他汀单药组(11.6% vs 15.2%;HR 0.75;95%CI 0.70-0.79;P<0.001),且他汀停药率和新发需药物治疗糖尿病发生率更低。

要点

  • 支架术后联合降脂较高强度他汀单药降低 3 年复合心血管事件风险。
  • 联合治疗组他汀停药率更低(6.5% vs 7.6%;HR 0.85;95%CI 0.78-0.94)。
  • 联合治疗组新发需药物治疗糖尿病更少(7.7% vs 9.6%;HR 0.80;95%CI 0.72-0.88)。

核心结论

  • 临床实践中,依折麦布联合中等强度他汀与药物洗脱支架植入术后患者更优的临床结局和用药依从性相关。

研究设计与样本

  • 观察性研究,基于全国队列数据库,经稳定逆概率加权后纳入 72,050 例药物洗脱支架植入后处方瑞舒伐他汀的患者。
  • 联合降脂组 10,794 例接受瑞舒伐他汀 10 mg 联合依折麦布 10 mg,单药组 61,256 例接受瑞舒伐他汀 20 mg。
  • 主要终点为 3 年复合事件:心血管死亡、心肌梗死、冠状动脉血运重建、心力衰竭住院治疗或非致死性卒中,依据 RACING 试验定义。

主要发现

  • 联合降脂组主要终点发生率为 11.6%,高强度他汀单药组为 15.2%(HR 0.75;95%CI 0.70-0.79;P<0.001)。
  • 联合降脂组他汀停药发生率为 6.5%,单药组为 7.6%(HR 0.85;95%CI 0.78-0.94;P<0.001)。
  • 联合降脂组新发需药物治疗糖尿病发生率为 7.7%,单药组为 9.6%(HR 0.80;95%CI 0.72-0.88;P<0.001)。

临床怎么用

  • 对于药物洗脱支架植入术后患者,可考虑依折麦布联合中等强度他汀作为降脂策略,以降低复合心血管事件并改善用药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases) trial examined the effects of combination therapy with moderate-intensity statin and ezetimibe in patients with atherosclerotic cardiovascular disease compared with high-intensity statin monotherapy. OBJECTIVES: This observational study was conducted to evaluate the impact of 2 treatment strategies used in the RACING trial in clinical practice. METHODS: After stabilized inverse probability of treatment weighting, a total of 72,050 patients who were prescribed rosuvastatin after drug-eluting stent implantation were identified from a nationwide cohort database: 10,794 patients with rosuvastatin 10 mg plus ezetimibe 10 mg (combination lipid-lowering therapy) and 61,256 patients with rosuvastatin 20 mg monotherapy. The primary endpoint was the 3-year composite event of cardiovascular death, myocardial infarction, coronary artery revascularization, hospitalization for heart failure treatment, or nonfatal stroke in accordance with the RACING trial. RESULTS: Combination lipid-lowering therapy was associated with a lower occurrence of the primary endpoint (11.6% vs 15.2% for those with high-intensity statin monotherapy; HR: 0.75; 95% CI: 0.70-0.79; P < 0.001). Compared with high-intensity statin monotherapy, combination lipid-lowering therapy was associated with fewer discontinuations of statin (6.5% vs 7.6%; HR: 0.85; 95% CI: 0.78-0.94: P < 0.001) and a lower occurrence of new-onset diabetes requiring medication (7.7% vs 9.6%; HR: 0.80; 95% CI: 0.72-0.88; P < 0.001). CONCLUSIONS: In clinical practice, combination lipid-lowering therapy with ezetimibe and moderate-intensity statin was associated with favorable clinical outcomes and drug compliance in patients treated with drug-eluting stent implantation. (CONNECT DES Registry; NCT04715594).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee SJ, Joo JH, Park S, et al. Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2023. PMID: 37495276. doi:10.1016/j.jacc.2023.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。